Azusa, California; August 11, 2006 – The results of Viral Genetics’ (OTCBB: VRAL) recent AIDS study of VGV-1 will be presented at the XVI International AIDS Conference in Toronto, Canada beginning August 13. The poster presentation focuses on what appeared to be beneficial immunological changes and the reduction in viral load seen after treatment in a subset of patients.

Viral Genetics’ VGV-1 is a suspension of thymus nuclear protein that has been tested in several studies in HIV infected individuals. In the recent 137-patient study, statistically significant antiviral effects were observed in treated subjects vs. placebo 100 days after the completion of dosing.

Results indicate statistically significant reductions in viral load (the amount of HIV in the blood) in some patients, only mild adverse events attributed to the drug, and a mechanism of action that may be markedly different than existing HIV therapies.

Additional results and study data is available by request at info@viralgenetics.com . The poster will be made available on the company’s website following the conference.

The World Health Organization estimates approximately 40 million people are now living with HIV. Even with the available treatments for AIDS, there are large numbers of people that need alternative therapies and hope remains that progress will be made in discovering new therapies that bolster patients’ immune systems.

About VGV-1

VGV-1 is a therapy based on thymus nuclear protein which is extracted from bovine thymus tissue. As a type of immune-based therapy, it focuses on boosting the immune system to allow the body to fight HIV more efficiently. It was discovered by Dr. Zhabilov Sr. and has been studied in five human clinical trials for the treatment of HIV infection and AIDS.

About XVI International AIDS Conference

XVI International AIDS Conference, beginning in Toronto on August 13, is the largest biannual AIDS conference with participation of over 20,000 delegates and 3,000 journalists. Featured keynote speakers include former US president Bill Clinton and Bill and Melinda Gates. Other major speakers include NIAID Director Anthony Fauci, UNAIDS Executive Director Peter Piot, and UN Special Envoy for HIV/AIDS in Africa Stephen Lewis.

About Viral Genetics

Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound. This compound may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. Online at www.viralgenetics.com 

For additional information, please contact Kirsten Ayars at 805-452-7909. For investor inquiries, please contact Kathy Lane at 760-771-2236.

This news release contains forward-looking statements that involve risks and uncertainties associated with clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but no limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

###

Kirsten Ayars

Ayars & Associates

strategic public affairs consulting

805.452.7909 * fax 425.699.9353

kayars@cox.net  * kayars@tynangroup.com